Skip Navigation


Mutagenesis Advance Access originally published online on December 8, 2006
Mutagenesis 2007 22(1):15-33; doi:10.1093/mutage/gel055
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/1/15    most recent
gel055v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Thomas, P.
Right arrow Articles by Fenech, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, P.
Right arrow Articles by Fenech, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author 2006. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

A review of genome mutation and Alzheimer's disease

Philip Thomas1,2,* and Michael Fenech1,*

1 CSIRO Health Sciences and Nutrition, PO Box 10041 Adelaide BC, Adelaide, South Australia 5000, Australia 2 Discipline of Physiology, School of Molecular and Biomedical Sciences The University of Adelaide, Adelaide, South Australia 5000, Australia

Alzheimer's disease (AD) is a complex progressive neurodegenerative disorder of the brain and is the commonest form of dementia. The prevalence of this disease is predicted to increase 3-fold over the next 30 years and to date no reliable and conclusive diagnostic test exists that will identify individuals presymptomatically of susceptibility risk. This review examines the molecular, genetic, dietary and environmental evidence underlying the known pathology of AD and proposes a biologically plausible chromosome instability model to explain some of the features of the disease. Genome damage biomarkers such as aneuploidy of chromosome 17 and 21, oxidative damage to DNA and telomere shortening together with abnormal expression of APP, ß amyloid and tau proteins are discussed in terms of their potential value as risk biomarkers. These biomarkers could then be used in diagnosis and the evaluation of potentially effective preventative measures.

*To whom correspondence should be addressed. Email: Michael.Fenech{at}csiro.au; and Philip.Thomas{at}csiro.au


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
J. M. Battershill, K. Burnett, and S. Bull
Factors affecting the incidence of genotoxicity biomarkers in peripheral blood lymphocytes: impact on design of biomonitoring studies
Mutagenesis, November 1, 2008; 23(6): 423 - 437.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
P. Thomas and M. Fenech
Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease
Mutagenesis, January 1, 2008; 23(1): 57 - 65.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
P. Thomas, J. Hecker, J. Faunt, and M. Fenech
Buccal micronucleus cytome biomarkers may be associated with Alzheimer's disease
Mutagenesis, November 1, 2007; 22(6): 371 - 379.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.